Blue Jet Healthcare Limited Stock Bombay S.E.

Equities

BLUEJET

INE0KBH01020

Pharmaceuticals

Market Closed - Bombay S.E. 06:01:20 2024-06-04 EDT 5-day change 1st Jan Change
359.2 INR -6.75% Intraday chart for Blue Jet Healthcare Limited -3.60% -2.40%

Financials

Sales 2024 7.12B 85.18M 117M Sales 2025 * 10.03B 120M 164M Capitalization 66.99B 802M 1.1B
Net income 2024 1.64B 19.61M 26.86M Net income 2025 * 2.28B 27.32M 37.42M EV / Sales 2024 8.89 x
Net cash position 2024 3.19B 38.13M 52.23M Net cash position 2025 * 2.58B 30.89M 42.32M EV / Sales 2025 * 6.42 x
P/E ratio 2024
40.6 x
P/E ratio 2025 *
29.4 x
Employees 407
Yield 2024
0.26%
Yield 2025 *
0.75%
Free-Float 12.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.75%
1 week-3.60%
Current month-6.04%
1 month-5.82%
3 months+2.78%
6 months+0.74%
Current year-2.40%
More quotes
1 week
346.70
Extreme 346.7
390.80
1 month
346.70
Extreme 346.7
390.80
Current year
324.45
Extreme 324.45
420.20
1 year
319.40
Extreme 319.4
433.25
3 years
319.40
Extreme 319.4
433.25
5 years
319.40
Extreme 319.4
433.25
10 years
319.40
Extreme 319.4
433.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 30 15-12-07
Director of Finance/CFO - 21-10-31
Chief Tech/Sci/R&D Officer - 20-10-20
Members of the board TitleAgeSince
Director/Board Member 64 22-04-12
Director/Board Member 45 22-07-31
Director/Board Member 52 22-04-12
More insiders
Date Price Change Volume
24-06-04 359.2 -6.75% 8 519
24-06-03 385.2 +0.76% 13,777
24-05-31 382.3 +2.03% 1,785
24-05-30 374.7 -0.03% 4,229
24-05-29 374.8 +0.59% 3,570

Delayed Quote Bombay S.E., June 04, 2024 at 06:01 am

More quotes
Blue Jet Healthcare Limited is an India-based specialty pharmaceutical and healthcare ingredients and intermediates company. The Company’s operations are primarily organized in three product categories: contrast media intermediates, high-intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Its high-intensity sweetener business includes development, manufacturing and marketing of saccharin and its salts. The Company’s contract development and manufacturing organization (CDMO) activity in the pharma intermediate and API business is primarily focused on collaborating with innovator pharmaceutical companies and multi-national generic pharmaceutical companies by providing them with pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
386.2 INR
Average target price
406.7 INR
Spread / Average Target
+5.30%
Consensus

Annual profits - Rate of surprise